• Potential to Redefine Dry Eye Disease Drug Therapies with EyeSol®

    Our products target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials


Dry eye disease (DED) is a global, multifactorial and complex disease of the ocular surface. Currently more than 18 million Europeans and 16 million Americans are diagnosed with DED.

The majority of diagnosed DED patients fail to get a satisfactory response with current treatments. Over 60% of patients using currently approved drug therapies in the U.S. discontinue their treatment within 12 months of initiation. In particular, local intolerabilities and lack of efficacy are considered to be key reasons for the high discontinuation rates.

EyeSol®, Novaliq’s unique and proprietary water-free technology, opens completely new and intriguing opportunities to target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials.


Novaliq offers an industry-leading portfolio of water-free topical products.

Our water-free technology, opens completely new and intriguing opportunities to cure, relief and prevent diseases in various indications.

Approved CE products: Novatears®, Novatears®+Omega-3

Novaliq has a rich pre-clinical pipeline covering a wide range of topical therapies in both, Ophthalmology and Dermatology.

For our products we only use highly pure substances and raw materials from qualified manufacturers. We have extensively tested and proven their safety, efficacy and tolerability in close cooperation with the regulatory authorities in Europe and USA, both preclinically and clinically.